Hancock Whitney sets April 21 call to review Q1 2026 results

Jefferies cut its price target for NextEra Energy (NYSE:NEE) to $87 from $94, citing regulatory uncertainty. The stock is trading at $77.06, near its 52-week low. Jefferies maintains a Hold rating, noting mixed but constructive regulatory approvals and upcoming testimonies. NextEra has raised its dividend for 30 consecutive years, currently yielding 3.23%.

Stifel kept its Hold rating and $100 price target on Lululemon (LULU) after leadership changes. The stock trades near its 52-week low, down 56% YTD. Lululemon reported a 4.3% Q2 revenue decline to $2.42B. Analysts cite weak demand and increased promotions. LULU's board expanded to 12 members with new CEO Heidi O'Neill.

NVIDIA is investing in both proprietary and open-source AI models, including a $90M Series B round for Nous Research, valuing it at $1.5B. Nous claims its Hermes 4.3 model outperforms GPT-4o in key metrics, but lacks independent verification. The company aims to compete with lower pricing, offering $0.30 per million tokens compared to competitors' higher rates. NVIDIA's strategy ensures its hardware remains central to AI infrastructure regardless of the winning model architecture.

Piper Sandler initiated coverage of LCNB Corp. with a Neutral rating and $20 price target, citing its lower-cost funding, revenue diversity, and regional scarcity. The target is based on 11x 2027 EPS, a premium to peers. LCNB has a P/E of 10.98, a 4.71% dividend yield, and steady loan growth prospects of 2% in 2027, according to Piper Sandler.

Quantum computing stocks like IONQ, QBTS, RGTI, and QUBT fell sharply on Wednesday due to rising U.S. Treasury yields, which increased borrowing costs and affected valuations of speculative tech companies. The 10-year Treasury yield briefly hit 5.36%, its highest since 2002. IonQ announced a $300 million DARPA agreement after market close, unrelated to the day's decline.

Biohaven (BHVN) has licensed its IgG degrader portfolio to Ono Pharma for Asian markets, including Japan and South Korea. The deal includes up to $100M in payments, with Biohaven retaining rights outside these regions. The portfolio, led by BHV-1300 in Phase 3 trials for Graves' disease, aims to treat autoimmune disorders. Biohaven's stock closed at $11.88, up 1.18% in pre-market trading.